{"id":75102,"title":"Omega Diagnostics Group (ODX.L) Preliminary report published by Ulster University","publisher":"Share Talk","author":"sharetalk","published":"2020-10-02T11:58:13+00:00","modified":"2020-10-02T11:58:13+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-group-odx-l-preliminary-report-published-by-ulster-university/","markdown_url":"https://www.share-talk.com/omega-diagnostics-group-odx-l-preliminary-report-published-by-ulster-university.md","json_url":"https://www.share-talk.com/omega-diagnostics-group-odx-l-preliminary-report-published-by-ulster-university.json","category":"Healthcare","categories":["Healthcare"],"tags":["Colin King","COVID-19","ODX","Omega Diagnostics Gp"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Omega (AIM: ODX),** the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of the preliminary report of an independent evaluation of Abc-19TM by Ulster University.\n\nThe independent report compares three commercially available immunoassays to evaluate performance metrics for the AbC-19TM lateral flow test, which is developed by the UK-RTC. The report notes the lack of a well-accepted gold standard assay against which to measure any newly developed immunoassay designed to detect antibodies to SARS-CoV-2.\n\nTo overcome these challenges, a ‘pseudo gold standard’ system was established against which to analyse the sensitivity and specificity of each of the three commercially available immunoassays using a well-characterised serology sample set to evaluate performance metrics for the AbC-19TM test. Using the ‘pseudo gold standard’ system the report concludes that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).\n\nA link to the preliminary report can be found here:\n\n[https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1](https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1)"}